A Look at Immunovaccine’s Major Recent Milestones

With the recent closing of its $10 million bought deal offering, Immunovaccine (IMV:CA)(IMMVF) is now in prime position to advance its transformational cancer therapies to the next stage. The deal, which was previously announced in May, will allow the company to invest more in the research and development, as well as clinical advancement of its cancer and infectious disease vaccine candidates, namely its lead cancer vaccine DPX-Survivac. Based on the company’s novel proprietary DepoVax™ adjuvanting technology platform, DPX-Survivac is currently a key component in a number of combination cancer therapies in clinical trials.

“Following the successful closing of this deal, Immunovaccine is well financed to plan for a phase 1 clinical trial aimed at expanding the application of DPX-Survivac (its lead cancer vaccine) across multiple indications,” Frederic Ors, Immunovaccine’s Chief Executive Officer, stated recently. “The target of DPX-Survivac, survivin, is associated with more than 20 types of hematological and solid cancers. With this association, and its other unique properties, we have only just begun to scratch the surface of DPX-Survivac’s potential within our growing pipeline. We are excited to continue our aggressive pursuit of bringing groundbreaking immunotherapies to the many millions of underserved people living with difficult-to-treat cancers.”

Immunovaccine’s Current DPX-Surivac Studies

Immunovaccine’s DPX-Survivac, based on the DepoVax™ system, serves as a broad foundation that can be combined with other approaches to develop novel immunotherapies. Currently, the company is conducting a Phase 1b study with Incyte (INCY) to combine DPX-Survivac with Epacadostat and low-dose cyclophosphamide as a triple combination therapy to combat ovarian cancer. The study, which is being conducted at the Princess Margaret Cancer Centre, has produced positive early results.

In addition, the company is also conducting a Phase 2 study funded by Merck (MRK) that combines DPX-Survivac with Merck’s checkpoint inhibitor Pembrolizumab as a combination therapy for patients with recurrent, platinum-resistant ovarian cancer.

According to the American Cancer Society (ACS), Ovarian cancer ranks fifth in cancer deaths among women, and is the seventh most common cancer in women worldwide, according to the World Cancer Research Fundiv.

In addition, Immunovaccine recently announced a new Phase II investigator-sponsored Phase 2 clinical trial that would combine DPX-Survivac with a checkpoint inhibitor drug currently marketed by a large pharmaceutical company to treat diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma (NHL).

The Potential of DepoVax™ Platform

Immunovaccine’s DepoVax™ serves as the underlying platform of potential applications in treating cancer and infectious diseases. The patented oil-based formulation provides a controlled and prolonged exposure of antigens plus adjuvant to allow for rapid and sustained immune system response with single-dose effectiveness. In addition to ovarian cancer and DLBCL with DPX-Survivac, Immunovaccine is also pursuing a number of other indications using DepoVax™.

The company recently completed a Phase 1 clinical trial on DPX-RSV, a vaccine candidate for respiratory syncytial virus (RSV), and is in a Phase 1b/2 clinical study for DPX-E7, which targets cancers related to the human papillomavirus (HPV). It is also pursuing clinical projects to use DepoVax™ to help develop virus vaccines for diseases such as malaria and the Zika virus.

Earlier this month, Immunovaccine also introduced its inaugural scientific and clinical advisory committee (SCAC), which is comprised prominent industry researchers, clinicians and collaborators in the immune-oncology and virology fields to provide counsel for Immunovaccine’s research and development activities. The Committee helps to bolster Immunovaccine’s scientific resources by providing a deep pool of knowledge, data and access to draw from as it pursues the advancement of its applications based on the DepoVax™ platform.

With the recent closing of the $10 million financing and the establishment of the SCAC, Immunovaccine has made very significant strides in reinforcing its strategic advantages as it pursues its audacious goals of revolutionizing the fight against cancer.

In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.